Journal of the American College of Cardiology © 2002 by the American College of Cardiology Foundation Published by Elsevier Science Inc. Vol. 39, No. 12, 2002 ISSN 0735-1097/02/\$22.00 PII S0735-1097(02)01888-0

Epicardial Electrogram of the Right Ventricular Outflow Tract in Patients With the Brugada Syndrome

Using the Epicardial Lead

Satoshi Nagase, MD, Kengo Fukushima Kusano, MD, PHD, Hiroshi Morita, MD, PHD, Yoshihisa Fujimoto, MD, PHD, Mikio Kakishita, MD, PHD, Kazufumi Nakamura, MD, PHD, Tetsuro Emori, MD, Hiromi Matsubara, MD, PHD, Tohru Ohe, MD, PHD, FACC

Okayama, Japan

OBJECTIVES	We tried to record an epicardial electrogram directly, and we examined local electrograms before and after administration of a class IC anti-arrhythmic drug in patients with the Brugada syndrome.
BACKGROUND	Electrical heterogeneity of the epicardium in the right ventricular outflow tract (RVOT) has
	been thought to be related to the Brugada syndrome. However, an epicardial abnormality has
	not been demonstrated in patients with the Brugada syndrome.
METHODS	In five patients with a Brugada-type electrocardiogram (ECG), local unipolar electrograms
	were recorded at the epicardium and endocardium of the RVOT. To record the epicardial
	electrogram directly, we introduced an electrical guidewire into the conus branch (CB) of the
	right coronary artery. The duration of the local electrogram after termination of the QRS
	complex (DP) was measured before and after class IC anti-arrhythmic drug administration.
	The signal-averaged electrocardiogram (SAECG) was also obtained in all patients.
RESULTS	A definite DP was observed at the epicardium, but not at the endocardium. After
	administration of a class IC anti-arrhythmic drug, the DP at the epicardium was prolonged
	from 38 \pm 10 ms to 67 \pm 24 ms. The late potential corresponding to the DP at the
	epicardium was observed in all patients on the SAECG.
CONCLUSIONS	An epicardial electrogram can be recorded from the CB. Recording from the CB enables
	identification of an epicardial abnormality in patients with the Brugada syndrome. These
	abnormal electrograms may be related to a myocardial abnormality in the epicardium of
	patients with the Brugada syndrome. (J Am Coll Cardiol 2002;39:1992–5) © 2002 by the
	American College of Cardiology Foundation

The Brugada syndrome is an idiopathic ventricular fibrillation (VF) characterized by ST-segment elevation in the precordial leads, and is augmented by sodium channel blockers (1–3). It has been suggested that electrical heterogeneity, especially at the epicardium of the right ventricle, causes the ST-segment elevation and is related to the occurrence of polymorphic ventricular arrhythmias (4,5).

See page 1996

However, studies using body surface mapping or the signalaveraged electrocardiogram (SAECG) have suggested that a conduction delay exists in the anterior wall of the right ventricle or the right ventricular outflow tract (RVOT) in patients with the Brugada syndrome (6,7). However, endocardial mapping in a routine electrophysiologic study failed to demonstrate this electrical abnormality.

The conus branch (CB) arises at the right coronary ostium or within the first few millimeters of the right coronary artery. It runs on the surface of the free wall of the right ventricular outflow tract (RVOT-FW). Therefore, an electrogram obtained at the CB may reflect an epicardial electrogram at the RVOT-FW. In this study, we analyzed electrograms recorded at the CB and examined the effects of class IC anti-arrhythmic drugs in patients with the Brugada syndrome.

METHODS

Study group. Five male patients (age 45 ± 11 years) with the Brugada syndrome were studied. All patients had persistent ST-segment elevation in the precordial leads. In three patients, episodes of VF or aborted sudden cardiac death were observed (i.e., symptomatic patients). In the other two patients, no episodes of VF or aborted sudden cardiac death were observed, but VF was demonstrated with single or double extrastimulation at the RVOT-FW in the electrophysiologic study (i.e., asymptomatic patients). Routine studies, including cardiac echocardiography, coronary angiography, right and left ventriculography, radionucleography and endomyocardial biopsy, showed no evidence of structural heart disease.

Electrophysiologic study. After obtaining written, informed consent, an electrophysiologic study was performed in all patients.

After right coronary arteriography, an electrical guidewire (FloWire, Cardiometrics, California) was introduced into

From the Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan. Part of this manuscript was presented at the 22nd Annual Scientific Sessions of the North American Society of Pacing and Electrophysiology, May 2 to 5, 2001, Boston, Massachusetts, and published in abstract form (Pacing Clin Electrophysiol 2001;24 Suppl II:II677).

Manuscript received September 11, 2001; revised manuscript received February 14, 2002, accepted March 27, 2002.

Abbreviations and Acronyms			
CB	= conus branch		
DP	= local electrogram after termination of the QRS complex		
ECG	= electrocardiogram/electrocardiographic		
LAS ₄₀	= duration of low-amplitude signals $<40 \ \mu V$ in the terminal filtered QRS complex		
LP	= late potential		
RMS ₄₀	= root mean square voltage of the terminal 40 ms in the filtered QRS complex		
RVOT	= right ventricular outflow tract		
RVOT-FW	= free wall of the right ventricular outflow tract		
SAECG VF	signal-averaged electrocardiogramventricular fibrillation		

the CB through the right coronary artery. A local unipolar electrogram at the epicardium of the RVOT-FW was recorded at the tip of the wire, using a 30- to 400-Hz

bandwidth. A local unipolar electrogram at the endocardium was recorded using a 30- to 400-Hz bandwidth, by a quadripolar 6F deflectable catheter positioned at the endocardium at the RVOT-FW (Fig. 1A).

The duration of the local electrogram after termination of the QRS complex (DP) was measured before and after class IC anti-arrhythmic drug administration. Termination of the QRS complex was defined in lead V₅. Pilsicainide (0.7 to 1.0 mg/kg) was administered to Patients 1 to 4, and flecainide (1.0 mg/kg) was administered to Patient 5 as a bolus over a period of 10 min.

SAECG. The SAECG (ART 1200EPX; noise level <0.3 μ V, high-pass filtering of 40 Hz using a bidirectional four-pole Butterworth) was performed in all patients. The filtered QRS duration, the root mean square voltage of the terminal 40 ms in the filtered QRS complex (RMS₄₀) and the duration of low-amplitude signals <40 μ V in the terminal filtered QRS complex (LAS₄₀), were measured



Figure 1. (A) Fluoroscopic 30° right anterior oblique (RAO) and 60° left anterior oblique (LAO) views of the position of the electrical guidewire introduced into the conus branch through the right coronary artery for epicardial mapping (Epi), as well as the quadripolar deflectable catheter at the endocardium of the free wall at the right ventricular outflow tract for endocardial mapping (Endo). (B) Surface electrocardiographic leads V_1 , V_2 and V_5 and intracardiac electrograms of the epicardium (Epi) and endocardium (Endo) at the free wall at the right ventricular outflow tract before (Pre) and after (Post) the administration of a class IC anti-arrhythmic drug in Patient 1 (asymptomatic patient). A definite local electrogram was recorded after termination of the QRS complex at the epicardium (**arrows**), and the duration of the local electrogram after termination of the QRS complex after class IC anti-arrhythmic drug administration was more prolonged at the epicardium than at the endocardium in Patient 1.



Figure 2. (A to E) Surface electrocardiographic leads V_2 and V_5 , intracardiac electrograms of the epicardium (Epi) at the free wall at the right ventricular outflow tract and signal-averaged electrocardiogram (SAECG) in Patients 1 (A), 2 (B), 3 (C), 4 (D) and 5 (E). Patients 1 and 2 are asymptomatic patients, and Patients 3, 4 and 5 are symptomatic patients. The late potentials, represented by the **shaded area**, are positive in all patients, showing the root mean square voltage of the terminal 40 ms in the filtered QRS complex (RMS₄₀) <20 μ V and the duration of low-amplitude signals <40 μ V in the terminal filtered QRS complex (LAS₄₀) >40 ms, and correspond to a delayed potential after the QRS complex at the epicardium (**arrows**) in all patients. f-QRS = filtered QRS duration.

with SAECG. A late potential (LP) was considered to be positive when two criteria ($RMS_{40} < 20 \ \mu V$ and $LAS_{40} > 40 \ ms$) were met.

RESULTS

A definite DP was observed at the epicardium, but not at the endocardium. After administration of a class IC antiarrhythmic drug, the duration of the DP at the epicardium was prolonged from 38 ± 10 ms to 67 ± 24 ms (Fig. 1B). An LP corresponding to the DP at the epicardium was observed in all patients on the SAECG (Fig. 2).

DISCUSSION

The Brugada syndrome is an idiopathic VF of uncertain etiology (1-3). Several studies have suggested that electrical heterogeneity is related to the genesis of the Brugada syndrome (4,5). A depressed right ventricular epicardial action potential dome is the basis for the ST-segment elevation and leads to phase 2 re-entry as a trigger for

episodes of polymorphic ventricular arrhythmias. However, the existence of a conduction delay at the RVOT has been suggested in many reports (6,7). In addition, several clinical studies have suggested that spontaneous episodes of VF are triggered by premature ventricular contractions originating from the right ventricular free wall (8,9). However, this electrical abnormality was not demonstrated by endocardial mapping in a routine electrophysiologic study.

In patients with the Brugada syndrome, class IC antiarrhythmic drug administration could augment ST-segment elevation in the precordial leads, and spontaneous VF has sometimes been observed (3,10).

The CB arises at the right coronary ostium or within the first few millimeters of the right coronary artery. It runs on the surface of the RVOT-FW. In this study, we were able to directly record a unipolar epicardial electrogram at the RVOT-FW, by using an electrical guidewire introduced into the CB. There was a delayed potential at the QRS complex in the epicardium of the RVOT-FW, which was not demonstrated by endocardial mapping. Class IC antiarrhythmic drug administration augmented ST-segment elevation and also augmented the DP in the epicardium. An LP was observed on the SAECG in all patients and corresponded to the DP recorded on the epicardial electrogram. These abnormal electrograms were thought to reflect a myocardial abnormality in the epicardium.

Because the CB is attached to the left ventricular cavity through the low resistance of blood, it is quite possible that the DP recorded in the CB reflects not only local electrograms at the RVOT, but also remote regions such as the left ventricle. To exclude that possibility, left ventricular endocardial mapping was performed in all patients, and the DP was not demonstrated at the left ventricular endocardium in any of the patients. Furthermore, left ventricular epicardial electrograms of the great cardiac vein through the coronary sinus were recorded in some patients who did not show a DP.

Conclusions. Recording from the CB enables identification of an epicardial abnormality in patients with the Brugada syndrome. Class IC anti-arrhythmic drug administration worsens these abnormalities, which may play an important role in the occurrence of VF in patients with the Brugada syndrome.

Reprint requests and correspondence: Dr. Satoshi Nagase, Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine and Dentistry, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. E-mail: snagase@cc.okayama-u.ac.jp.

REFERENCES

- Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden death: a distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol 1992;20:1391–6.
- 2. Brugada J, Brugada R, Brugada P. Right bundle-branch block and ST-segment elevation in leads V_1 through V_3 : a marker for sudden death in patients without demonstrable structural heart disease. Circulation 1998;97:457–60.
- 3. Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000;101:510–5.
- 4. Yan GX, Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999;100:1660–6.
- 5. Gussak I, Antzelevitch C, Bjerregaard P, et al. The Brugada syndrome: clinical, electrophysiological and genetic aspects. J Am Coll Cardiol 1999;33:5–15.
- 6. Kasanuki H, Ohnishi S, Ohtuka M, et al. Idiopathic ventricular fibrillation induced with vagal activity in patients without obvious heart disease. Circulation 1997;95:2277–85.
- 7. Ikeda T, Sakurada H, Sakabe K, et al. Assessment of noninvasive markers in identifying patients at risk in the Brugada syndrome: insight into risk stratification. J Am Coll Cardiol 2001;37:1628-34.
- Kakishita M, Kurita T, Matsuo K, et al. Mode of onset of ventricular fibrillation in patients with Brugada syndrome detected by implantable cardioverter defibrillator therapy. J Am Coll Cardiol 2000;36:1646– 53.
- 9. Takagi M, Aihara N, Kuribayashi S, et al. Localized right ventricular morphological abnormalities detected by electron-beam computed tomography represent arrhythmogenic substrates in patients with the Brugada syndrome. Eur Heart J 2001;22:1032–41.
- 10. Takenaka S, Kusano F K, Hisamatsu K, et al. Relatively benign clinical course in asymptomatic patients with Brugada-type electrocardiogram without family history of sudden death. J Cardiovasc Electrophysiol 2001;12:2–6.